Last reviewed · How we verify

Huluc63 — Competitive Intelligence Brief

Huluc63 (elotuzumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SLAMF7-directed Immunostimulatory Antibody [EPC]. Area: Oncology.

marketed SLAMF7-directed Immunostimulatory Antibody [EPC] SLAM family member 7 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Huluc63 (elotuzumab) — Bristol-Myers Squibb. Huluc63 works by binding to the SLAMF7 protein on the surface of cancer cells, stimulating the immune system to attack and kill the cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Huluc63 TARGET elotuzumab Bristol-Myers Squibb marketed SLAMF7-directed Immunostimulatory Antibody [EPC] SLAM family member 7 2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SLAMF7-directed Immunostimulatory Antibody [EPC] class)

  1. Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Huluc63 — Competitive Intelligence Brief. https://druglandscape.com/ci/elotuzumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: